SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...
11h
Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...
Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of people around the world living with HIV.
Genomics, Inc. , a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Pathway to Cures (P2C) announced their annual fund update meeting on Wednesday, September 11th in Atlanta, Georgia. Pathway to Cures (P2C) is the venture philanthropy fund for the National Bleeding ...
Dear reader, in 2024, the pharmaceutical industry has undergone significant transformations due to rapid advancements in drug ...
The adaptation of immune cells to their local microenvironments in our body is central to tissue homeostasis and linked to ...
Researchers at Brigham and Women's Hospital discovered that individuals exhibiting a wide range of long COVID symptoms were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback